Novo Nordisk’s Pill Pivot Faces Its First Big Test on Wednesday
Novo Nordisk’s shift to oral GLP-1 drugs faces pricing pressure and Eli Lilly competition as Q1 earnings loom,…
Generics, Pipeline Wins, and a Pivotal Earnings Report
Novo Nordisk enters a pivotal week with Canada approving first Ozempic generics, oral Ozempic exceeding prescription expectations, and…
Q1 Earnings Loom as Valuation Debate Intensifies
Novo Nordisk faces pivotal Q1 earnings amid a 36% YTD stock drop, competitive pressure from Eli Lilly, and…
Generics, Q1 Results, and a Pipeline Showcase
Novo Nordisk enters a critical period with Q1 earnings, a Canadian Ozempic generic launch, and obesity conference data,…
Generics, Price Wars, and a Steep Valuation Gap
Novo Nordisk faces a turbulent period with a 20% stock drop, Eli Lilly’s US market dominance, and Canada’s…
Canadian Generic Launch and Q1 Results Loom
Health Canada authorizes Dr. Reddy’s biosimilar semaglutide, threatening Novo Nordisk’s Ozempic revenue as share buyback reaches 3.44 billion…
Novo Nordisk Faces a Fork in the Road as Pipeline Progress Meets Profit Pressure
Novo Nordisk stock trades 50% below peak amid GLP-1 competition from Eli Lilly’s oral pill, regulatory wins, and…
Novo Nordisk’s Strategic Pivot Faces Crucial First-Quarter Test
Novo Nordisk shares down 20% YTD as it faces new oral obesity drug competition from Eli Lilly and…
Novo Nordisk’s Pill Revenue Faces a Critical Quarter
Novo Nordisk raises Wegovy pill price as analysts cut targets over weak prescription mix. Stock is oversold amid…
Novo Nordisk’s Pill and Needle Strategy Faces a Competitive and Financial Crossroads
Novo Nordisk launches high-dose & oral Wegovy in the US and eases EU cold-chain rules to compete with…
Novo Nordisk Faces Mounting Challenges as Competition Intensifies
Novo Nordisk cuts 2026 sales outlook amid generic competition in India, U.S. price pressures, and Eli Lilly’s new…
Novo Nordisk Faces Pivotal Moment in Oral Weight-Loss Drug Race
Novo Nordisk releases Wegovy pill data ahead of Lilly’s launch as analysts cut targets citing competition and pipeline…